Food Allergy Biotech Firm Lycia Raises $317.5 Million in US IPO
Lycia Therapeutics Inc., a biotechnology firm focused on treatments for allergies and autoimmune diseases, raised $317.5 million in an upsized US initial public offering that priced at the top of...
By Avalon Pernell · Bloomberg
Lycia Therapeutics Inc., a biotechnology firm focused on treatments for allergies and autoimmune diseases, raised $317.5 million in an upsized US initial public offering that priced at the top of its marketed range.